CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy. There is an urgent need to collaborate on clinical trials and translational research and to unite leading experts.
The preferred candidates will have a combination of academic and clinical experience, with demonstrated clinical expertise in family medicine, will exhibit strong potential for innovative and scholarly research, and provide evidence of an ability to work in an interdisciplinary, collaborative environment. Clinical responsibilities will be based at the Queen’s Family Health Team in Kingston and include taking call approximately one (1) night per month and three (3) weekends per year.
The 2018 Clinical Trials Conference hosted by CTO – taking place March 27-28, 2018 at the Sheraton Hotel in Toronto – is an interactive and collaborative 2-day event that brings together over 350 people from industry, research, ethics, healthcare, non-profit, government and academia to exchange ideas, build relationships, and develop new strategies with respect to improving clinical trials and bringing more clinical trials to Ontario.
Online citations of previously published CCTG studies MA.27 and OV.21
CCTG is pleased to announce that Dr. Martin Smoragiewicz has joined the group as a Senior Investigator. Dr. Smoragiewicz is a medical oncologist who completed his undergraduate BSc and MD.CM at McGill University, and internal medicine and medical oncology training in British Columbia. He has completed a fellowship in early phase clinical trials at the University of Cambridge, focusing on immune approaches in pancreatic cancer as part of a PhD program. Dr. Smoragiewicz will be working with Lesley Seymour in the IND program.
The Quality of Life committee is currently seeking 2-3 individuals with enthusiastic interest in the measurement of patient-reported outcomes in clinical trials.
CCTG network researchers have been recognized by Governor General Julie Payette who announced the Order of Canada appointments on Friday, Dec. 29. Please join us in congratulating Dr. Pritchard, Dr. Gleave and Dr. Eisenhauer on this wonderful honour and for their outstanding contributions to cancer clinical trial research in Canada.
Links to online citations of previously published CCTG studies are listed here.
